Market Runner: A Reversal for AstraZeneca plc (ADR) Is Not Near. The Stock Declines Again

Market Runner: A Reversal for AstraZeneca plc (ADR) Is Not Near. The Stock Declines Again

The stock of AstraZeneca plc (ADR) (NYSE:AZN) is a huge mover today! About 1.82M shares traded hands. AstraZeneca plc (ADR) (NYSE:AZN) has risen 4.29% since March 11, 2016 and is uptrending. It has underperformed by 1.16% the S&P500.
The move comes after 7 months negative chart setup for the $76.37 billion company. It was reported on Oct, 14 by We have $28.31 PT which if reached, will make NYSE:AZN worth $6.11 billion less.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on November, 3. They expect $0.58 EPS, down 43.69% or $0.45 from last year’s $1.03 per share. AZN’s profit will be $1.44B for 13.26 P/E if the $0.58 EPS becomes a reality. After $0.83 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -30.12% negative EPS growth.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Barclays Capital upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Tuesday, January 19 to “Equal-Weight” rating. BNP Paribas downgraded the shares of AZN in a report on Wednesday, September 14 to “Neutral” rating. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Overweight” rating by Morgan Stanley on Tuesday, December 1. Cantor Fitzgerald initiated the stock with “Buy” rating in Friday, February 26 report. On Monday, February 8 the stock rating was downgraded by HBSC to “Hold”. On Monday, May 2 the stock rating was maintained by Leerink Swann with “Market Perform”. The company was upgraded on Wednesday, September 2 by HSBC. Argus Research upgraded the stock to “Buy” rating in Monday, August 29 report. S&P Research upgraded it to “Buy” rating and $38 target price in Friday, July 31 report. The rating was initiated by Piperjaffray with “Overweight” on Friday, September 23.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by which published an article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment